BDTX vs KYMR vs NUVL vs AUPH vs ERAS

For growth investors, Aurinia Pharmaceuticals Inc.

(AUPH) is the stronger pick with 20. 4% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Black Diamond Therapeutics, Inc. (BDTX) offers the better valuation at 7. 4x trailing P/E, making it the more compelling value choice. Analysts rate Black Diamond Therapeutics, Inc. (BDTX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Black Diamond Therapeutics, Inc.

(BDTX) is the cheapest at 7. 4x versus Aurinia Pharmaceuticals Inc. at 7. 7x.

Over the past 5 years, Nuvalent, Inc.

(NUVL) delivered a total return of +441. 2%, compared to -88. 4% for Black Diamond Therapeutics, Inc. (BDTX). Over 10 years, the gap is even starker: AUPH returned +487. 5% versus BDTX's -92. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Erasca, Inc.

(ERAS) is the lower-risk stock at 0. 78β versus Black Diamond Therapeutics, Inc. 's 2. 66β — meaning BDTX is approximately 241% more volatile than ERAS relative to the S&P 500. On balance sheet safety, Kymera Therapeutics, Inc. (KYMR) carries a lower debt/equity ratio of 5% versus 13% for Black Diamond Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aurinia Pharmaceuticals Inc.

(AUPH) is pulling ahead at 20. 4% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Aurinia Pharmaceuticals Inc. grew EPS 51. 7% year-over-year, compared to -81. 1% for Nuvalent, Inc.. Over a 3-year CAGR, AUPH leads at 28. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aurinia Pharmaceuticals Inc.

(AUPH) is the more profitable company, earning 101. 5% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 101. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37. 1% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BDTX: 178.

7% to $8. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aurinia Pharmaceuticals Inc.

(AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86), +487. 5% 10Y return). Black Diamond Therapeutics, Inc. (BDTX) carries a higher beta of 2. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AUPH: +487. 5%, BDTX: -92. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BDTX is a small-cap deep-value stock; KYMR is a small-cap quality compounder stock; NUVL is a small-cap quality compounder stock; AUPH is a small-cap high-growth stock; ERAS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.